Lyra Therapeutics, Inc.

LYRA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$40,577$22,353$32,550$45,747
Short-Term Investments$0$80,400$65,344$0
Receivables$0$0$0$0
Inventory$0$0$0$0
Other Curr. Assets$2,448$2,068$2,935$2,171
Total Curr. Assets$43,025$104,821$100,829$47,918
Property Plant & Equip (Net)$21,328$35,276$4,466$5,858
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$1,993$1,392$0$0
Tax Assets$0$0$0$0
Other NC Assets$0$1,111$4,673$1,091
Total NC Assets$23,321$37,779$9,139$6,949
Other Assets$0$0$0$0
Total Assets$66,346$142,600$109,968$54,867
Liabilities
Payables$1,179$3,131$2,616$3,125
Short-Term Debt$4,121$5,434$3,510$1,074
Tax Payable$0$0$0$0
Deferred Revenue$398$1,658$1,275$9,789
Other Curr. Liab.$6,933$9,374$7,069$4,258
Total Curr. Liab.$12,631$19,597$14,470$18,246
LT Debt$30,259$21,447$667$379
Deferred Rev, NC$11,862$12,136$14,077$1,926
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$42,121$33,583$14,744$2,305
Other Liabilities$0$0$0$0
Cap. Leases$34,380$26,881$4,177$1,453
Total Liabilities$54,752$53,180$29,214$20,551
Equity
Pref Stock$0$0$0$0
Common Stock$65$57$32$13
Retained Earnings-$404,790-$311,355-$248,675-$193,397
AOCI$0$33$10$0
Other Equity$416,319$400,685$329,387$227,700
Total Equity$11,594$89,420$80,754$34,316
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$66,346$142,600$109,968$54,867
Net Debt-$6,197$4,528-$28,373-$44,294